Brian is in charge of overall China coverage within the APAC pharma news team. A veteran journalist, he has written extensively on R&D, regulatory, market access and business issues. Brian has led a team of writers providing industry-leading coverage in the second-largest health care market.
Latest From Brian Yang
COVID Lessons Mean New Vaccine Approach Needed In China, Exec Says
CEO of Chinese vaccine developer BravoVax shares views with Scrip on pandemic lessons learned and new approaches needed to move forward.
Chinese Biotech Expects Limited Impact From SVB Aftermath
Favored by venture capital funds, Silicon Valley Bank has served biotech firms conducting transactions in the US. But its collapse is generating a ripple effect on Chinese start-ups already hard hit by a funding crunch.
A Closing Door? New China Leadership Takes Reins Amid Growth Anxiety
China's just-concluded National Congress elected new senior government leadership, but shifting top-level policy priorities and a worsening wider operating environment mean observers are worried about continued growth and ongoing pressures on drug pricing.
Controversial China Gene Editing Scientist's New Activities Prompt Criticism, Support
Previously jailed gene editing scientist Jiankui He was absent from a recent international genome editing summit, but his renewed activities are generating new concerns five years after the Chinese researcher shocked the world by announcing the birth of gene-edited babies.
China New Government Policies Taking Shape As Two Sessions Underway
Moderate growth goal and lingering impact from COVID policies dampen prospects of a quick recovery for China.
China Business Pessimism Grows Amid COVID Origin Assessment, Congressional Hearing
Simmering US-China tensions dash hopes that a recent border reopening will put many collaborations back on track, even as more than half foreign businesses now downgrade the importance of investing in China.